Oil prices hold sharp losses with focus on secondary India tariffs
Repligen (NASDAQ:RGEN) Corporation’s stock has experienced a notable downturn, with shares currently trading at $107.79, below its recent 52-week low of $113.24. This latest price level reflects a significant retreat from previous valuations, marking a stark contrast to the more robust trading periods in the past year. According to InvestingPro data, analyst price targets range from $140 to $225, suggesting potential upside despite recent weakness. Investors have witnessed a substantial 1-year change in the stock’s performance, with Repligen’s shares declining by 29.63%. This downturn has prompted market analysts and investors alike to closely monitor the bioprocessing company’s financial health and industry prospects. The company maintains strong liquidity with a current ratio of 8.41 and operates with moderate debt levels. InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of Repligen’s $6.08 billion market cap operation.
In other recent news, Repligen Corporation reported its fourth-quarter and full-year financial results for 2024, with fourth-quarter revenue reaching $167.5 million, a 1% increase from the previous year. The company’s adjusted earnings per share for the quarter were $0.44, slightly below the previous year’s $0.48. Repligen’s full-year revenue for 2024 was $634.4 million, aligning with analysts’ projections. Looking ahead, the company has set its 2025 revenue guidance between $685 million and $710 million, with anticipated GAAP net earnings per diluted share ranging from $0.90 to $0.99.
Repligen also announced the acquisition of a bioprocessing desktop portfolio for $70 million, which is expected to add $10 million in inorganic sales for the current year. This acquisition aligns with Repligen’s strategic growth plans and is expected to bolster its upstream capabilities. Analyst firms have varied in their outlooks, with Evercore ISI assigning an In Line rating and a $155 price target, while Leerink Partners maintained an Outperform rating with a $200 target.
Additionally, H.C. Wainwright reaffirmed a Buy rating with a $180 price target, and Canaccord Genuity raised its price target to $170 while maintaining a Hold rating. These ratings reflect differing perspectives on Repligen’s growth potential and market position as the bioprocessing industry shows signs of recovery.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.